NCT03526991 (SCS for FOG) is a NA clinical trial of Spinal Cord Stimulator (SCS) in Parkinson Disease, sponsored by Nora Vanegas.

Who is sponsoring NCT03526991?

NCT03526991 is sponsored by Nora Vanegas.

What drugs are being tested in NCT03526991?

Interventions in NCT03526991: Spinal Cord Stimulator (SCS).

What condition does NCT03526991 study?

NCT03526991 studies Parkinson Disease.

Is NCT03526991 still recruiting?

NCT03526991 is currently completed. Last updated 19 March 2026.

Last reviewed 2026-03-19 · How we verify

NCT03526991: SCS for FOG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.

Completed NA Last updated 19 March 2026

What this trial tests

NA trial testing Spinal Cord Stimulator (SCS) in Parkinson Disease in 10 participants. Completed in 28 February 2026.

Timeline

1 August 2021

Primary endpoint
28 February 2026

28 February 2026

Quick facts

Lead sponsor	Nora Vanegas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	device feasibility
Enrollment	10
Start date	1 August 2021
Primary completion	28 February 2026
Estimated completion	28 February 2026
Sites	2 locations across United States

Drugs / interventions tested

Spinal Cord Stimulator (SCS)

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Nora Vanegas

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. Recent research in animal models and clinical human data using SCS has produced promising results, specifically showing improvement in FOG with the use of SCS in patients with PD. The purpose of this study is to evaluate the effectiveness of spinal cord stimulation (SCS) for the management of freezing of gait (FOG) that does not respond to conventional treatments in subjects with Parkinson's disease (PD). The investigators hypothesize that SCS significantly decreases FOG episodes in patients with PD. 1. Assess the safety, tolerability and preliminary evidence of effectiveness of upper thoracic spinal cord stimulation for freezing of gait in Parkinson's (PD) patients. 2. Explore the effects of two SCS programming paradigms on motor, nonmotor and quality of life measures in PD patients with freezing of gait.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Spinal cord stimulation in Parkinson's disease: a review of the preclinical and clinical data and future prospects.
Cai Y, Reddy RD, Varshney V, Chakravarthy KV. · · 2020 · cited 20× · PMID 32232113 · DOI 10.1186/s42234-020-00041-9

Verify or expand the search:

Other trials of Spinal Cord Stimulator (SCS)

Trials testing the same drug.

NCT07091123 — Patient Preference and Long-term Outcomes in Persistent Spinal Pain Syndrome: A Prospective Study Comparing Spinal Cord · Phase 4 · recruiting
NCT06272955 — LONG TERM EFFECTS OF SPINAL CORD STIMULATION · unknown

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Nora Vanegas trials

Trials by the same sponsor.

NCT06991335 — VC/VS for Apathy in PD · NA · not yet recruiting
NCT06272955 — LONG TERM EFFECTS OF SPINAL CORD STIMULATION · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03526991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nora Vanegas
Last refreshed: 19 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing